What happens inside a patellofemoral OA joint

At the front of the knee, the kneecap (patella) slides up and down within a shallow channel on the thigh bone called the trochlear groove. This articulation — the patellofemoral joint — is a mechanically distinct compartment, entirely separate from the medial and lateral compartments where the femur meets the tibia. Its primary role is to amplify the force of the quadriceps muscle during activities that require bending the knee under load: descending stairs, squatting, cycling, and rising from a chair.

In patellofemoral osteoarthritis (PFOA), the cartilage on the underside of the patella and on the facing trochlear surface gradually breaks down. As that cushioning layer thins and roughens, the joint loses its ability to distribute load smoothly, and friction between the two bony surfaces increases. The underlying bone begins to remodel in response — and crucially, the two processes happen together rather than in sequence.

2024 PET/MRI imaging of patients with isolated PFOA — meaning no involvement of the tibiofemoral compartments — confirmed this co-evolution directly: subchondral bone activity (measured by ¹⁸NaF uptake) and changes in cartilage composition were both linked to peak vertical impact loading rates during walking, pointing to mechanical load as the driver of deterioration specifically within this compartment. PFOA is not an early or milder version of generalised knee arthritis; it is a compartment-specific condition with its own mechanical logic, its own pattern of tissue change, and — as later sections cover — its own distinct clinical picture.

How PFOA differs from tibiofemoral knee OA

The location of pain gives the first clue. With PFOA, discomfort sits at the front of the knee and flares predictably during activities that press the patella into the trochlear groove: walking downstairs, squatting, rising from a low chair, or sitting with the knee bent for long periods. Flat-ground walking is often well-tolerated, at least in the earlier stages. Tibiofemoral OA tends to behave the other way round — sustained level walking is what aggravates it, and the pain sits along the inner or outer joint line rather than at the front.

The clinical signs that accompany these symptom patterns are equally distinct. A 2012 population-based study of 745 people aged 50 and over with knee pain (Peat et al., PMC3446431) formally characterised the two conditions. Moderate-to-severe isolated PFOA was associated with coarse crepitus — a grating or grinding sensation when the knee bends — together with valgus (knock-knee) alignment and noticeably reduced quadriceps strength. Tibiofemoral OA, by contrast, was more likely to produce visible joint swelling (effusion), bony enlargement around the joint line, reduced flexion range, mediolateral instability, and varus (bow-legged) alignment.

Neither condition is inherently more serious than the other. They are simply different in anatomy, in the movements that provoke symptoms, and in the physical findings a clinician looks for — which is why accurate compartment-level diagnosis matters before any treatment plan is formed.

Who develops PFOA and why loading matters

Several factors raise the likelihood of developing PFOA, and most share a common thread: they either increase the force the patellofemoral cartilage must absorb or reduce its ability to distribute that force evenly.

Women are disproportionately affected and, on average, report greater pain and disability than men. Gait studies confirm this reflects genuine biomechanical differences rather than reporting style — female patients with PFOA walk with lower knee flexion and adduction moments and lower vertical ground reaction forces, altering how load passes through the joint across every step.

Prior knee injury (including ACL trauma), quadriceps weakness, valgus (knock-knee) alignment, and higher BMI are each independently recognised contributors. When the quadriceps cannot generate force efficiently, or when the kneecap tracks slightly off-centre through the trochlear groove, load concentrates on a smaller area of cartilage — the conditions under which breakdown accelerates.

One important nuance is that cartilage and bone changes visible on imaging do not reliably predict how much pain a person experiences. Because symptoms tend to track loading behaviour more closely than scan findings, targeting load directly — through strengthening, alignment correction, and weight management — is more actionable than waiting for structural confirmation before intervening. Conservative approaches grounded in this logic aim to change the mechanical environment the joint operates in, not simply to mask pain as a secondary outcome.

Getting a diagnosis and what to expect from assessment

Confirming a PFOA diagnosis involves more steps than a routine GP appointment typically allows. A specialist assessment begins with a careful history — establishing which activities provoke symptoms — and then moves to physical examination: checking patellar alignment, testing quadriceps strength, and feeling for crepitus as the knee moves through its range.

At early grades, the condition is genuinely difficult to pin down. A population-based study of 745 people aged 50 and over (Peat et al., 2012) reported a diagnostic accuracy of only around 0.71 AUC for early isolated PFOA — a meaningfully limited figure. A normal-seeming examination does not rule the condition out, and a degree of diagnostic uncertainty at the mild end is normal rather than a clinical failure.

Imaging choice matters considerably. A standard anteroposterior (AP) knee X-ray evaluates the tibiofemoral compartment but gives a poor view of the patellofemoral joint; if that is the only image taken, the compartment may not have been adequately assessed. Lateral and Merchant (skyline) views are the appropriate projections for visualising patellar tilt, joint-space narrowing, and osteophyte formation at the front of the knee. MRI adds useful further detail — on cartilage integrity and subchondral bone status — but should be read as one input into the clinical picture, not as a standalone verdict. Symptoms and imaging findings do not always correspond.

Severity grading matters for what follows. Isolated mild-to-moderate PFOA carries a different realistic treatment pathway than end-stage bilateral patellofemoral involvement, and the two should not be managed identically.

Conservative management and when to consider escalation

For most people with PFOA, structured physiotherapy is both the recommended starting point and, for many, sufficient to achieve meaningful improvement without progressing to injections.

The core of any programme is quadriceps strengthening. Strong quadriceps generate force across the patella more evenly, reducing the peak contact stress that falls on already-compromised cartilage during stair descent, squatting, and rising from a chair. Alongside this, load management — modifying activities that drive symptoms while preserving fitness through lower-impact alternatives — helps prevent the cycle of flare and avoidance that can accelerate functional decline over time.

Supportive measures such as patellar taping, a patellofemoral brace, or targeted weight management can reduce joint loading further between sessions. None of these requires a referral and all can run in parallel with physiotherapy from the outset.

A structured course of eight to twelve weeks gives the programme a genuine opportunity to deliver change. If pain and functional limitation remain significant despite consistent engagement, intra-articular injections are the next realistic option for many patients — and what the following section addresses.

Injection options for isolated PFOA and what the evidence shows

Most injection research has focused on the tibiofemoral compartment, so evidence specific to isolated PFOA is limited — but growing. The following reflects that hierarchy honestly.

Corticosteroid and hyaluronic acid

The most direct evidence comes from a 2025 double-blind RCT (n=60, isolated PFOA) comparing a single intra-articular injection of 2% sodium hyaluronate against triamcinolone acetonide corticosteroid. Both produced significant VAS pain reductions and Kujala function improvements sustained to six months, with no meaningful difference between groups at that endpoint.

The key distinction is timing. Corticosteroid delivered significantly greater pain relief in the first week — VAS differences of approximately 10 points at 48 hours and 7.7 points at one week — making it the pragmatic choice when rapid symptom control is the priority, as in an acute flare. Hyaluronic acid is a valid alternative for patients who prefer to avoid steroid exposure or want a sustained, lubrication-focused approach over a longer period.

Arthrosamid (polyacrylamide hydrogel)

One published case report describes a reduction in patellofemoral bone marrow lesions following a single intra-articular Arthrosamid injection in a patient with advanced PFOA. This is case-level evidence; no controlled trial in this specific compartment is available, so strong claims are not warranted at this stage.

Bone marrow concentrate (BMC)

A 2025 retrospective case series (n=7) found significant WOMAC score improvement at 12 months alongside a non-significant trend toward greater healthy cartilage volume on MRI. Larger controlled trials are absent, placing this firmly in the exploratory category.

PRP

Platelet-rich plasma appears in clinical overviews for active patients seeking to delay surgery, but no PFOA-specific RCT has been identified. Any benefit is extrapolated from general knee OA evidence.

Choosing between them

The timing distinction offers the clearest practical guide: corticosteroid where fast relief is needed for a flare; hyaluronic acid where comparable six-month outcomes are acceptable and avoiding repeated steroid exposure is a priority. Arthrosamid and BMC are reasonable topics for a specialist conversation when first-line options have not delivered sufficient benefit. For end-stage isolated PFOA, patellofemoral arthroplasty is an established surgical option.

1. [1] Sex-related differences in gait characteristics and associations with symptoms in PFOA (2023). (2023). https://doi.org/10.1016/j.gaitpost.2023.09.009 https://doi.org/10.1016/j.gaitpost.2023.09.009
2. [2] Analysis of Risk Factors on Patellofemoral Osteoarthritis: Distribution Characteristics and Radiographic Parameters (2024). (2024). https://doi.org/10.1111/os.14271 https://doi.org/10.1111/os.14271
3. [3] Patellofemoral bone remodeling, cartilage composition, and vertical loading rate: PET/MRI in isolated PFOA (2024). (2024). https://doi.org/10.1016/j.joca.2024.09.001 https://doi.org/10.1016/j.joca.2024.09.001
4. [4] Efficacy of Single Intra-articular 2% Sodium Hyaluronate versus Corticosteroid Injection in Isolated Patellofemoral Osteoarthritis: A Double-Blind, RCT (2025). (2025). https://doi.org/10.1016/j.jisako.2025.101038 https://doi.org/10.1016/j.jisako.2025.101038
5. [5] Intra-Articular Injection of Bone Marrow Concentrate for Patellofemoral Osteoarthritis Treatment (2025). (2025). https://doi.org/10.3390/bioengineering12111150 https://doi.org/10.3390/bioengineering12111150